Trump Defends Russian Diesel Deal Amid US Sanctions Backlash 
Asian Currencies Steady as Dollar Nears 18-Month High Ahead of US CPI 
Bumble Shares Surge 50% on $1 Billion Buyout Talks 
Arthur Hayes Announces FLOP Testnet Launch Within Weeks 
Apple Supplier Luxshare Faces US Patent Probe, Sees Limited Impact 
Moonshot AI Executives Seek Settlement Ahead of Hong Kong IPO 
Gold Prices Hit One-Week High as Oil Falls, Fed Rate Outlook Weighed 
US Dollar Rises for Fourth Week as Fed Rate Hike Bets Grow 
UK Finance Minister Healey Calls for Fiscal Discipline Amid Global Risks 
Deutsche Bank CEO Urges Faster German Economic Reforms 
Morgan Stanley Predicts $10 Trillion RWA Market by 2030 
Gold Prices Rebound as Dollar Weakens Ahead of US Inflation Data 
Asian Stocks Plunge as AI Chip Selloff Hits South Korea and Japan 
Coinbase CEO Backs SEC Accredited Investor Reform 
Syndax Stock Drops 15% After Axatilimab Trial Failure 
US Dollar Near 18-Month High Ahead of Inflation Data 
Visa Wins China Approval to Prepare Domestic Payments Expansion 
Add as a preferred source on Google
Merck & Co Inc. gets the green light from the Japanese health ministry for its COVID-19 anti-viral pill. The health officials recommended the approval of the said medicine late last week.
The approval of the Merck coronavirus pill is said to be part of the country’s Prime Minister Fumio Kishida’s plan to introduce and distribute new treatments by the end of the year as the growing cases of Omicron variant infection is becoming a very serious concern.
According to Inquirer.net, the committee’s decision has led to the shipments of around 200,000 doses starting this weekend. This is just the preparation and start of the deliveries as per the announcement of the country’s prime minister.
“I am convinced the distribution of this drug is a major step forward for our nation’s COVID–19 handling,” Shigeyuki Goto, Japan’s health minister, told the press after the announcement of the panel’s approval of Merck’s COVID-19 treatment pill.
He added that some of the country’s pharmacies and medical institutions are expected to begin receiving the medicine as early as next Monday. Moreover, it was said that Japan is really laying bets on oral treatments to prevent cases of severe infections and deaths should a sixth wave of the pandemic arise.
Based on the report, Japan agreed to pay $1.2 billion to Merck and its partner Ridgeback Biotherapeutics for the shipment of 1.6 million courses of molnupiravir. PM Kishida also said last week, the government signed a deal for two million doses of another anti-viral treatment pill and this was developed by Pfizer.
In the U.S., health regulators also authorized the use of the Merck pill for some high-risk adult patients. Many countries are now rushing to purchase the said Merck’s molnupiravir due to promising results during trials.
“As a single oral medicine that can be taken at home, early treatment with molnupiravir significantly reduced the risk of hospitalization or death in patients at high risk for progressing to severe COVID-19,” Merck research laboratories president, Dr. Dean Y. Li, said in a press release. “Importantly for patients, there were markedly fewer deaths among those taking molnupiravir in our clinical study and we believe that it will be a critical addition to the measures available to help curb the impact of COVID-19 on patients, healthcare systems, and public health in Japan.”
